Combination therapy in autoimmune disease: vasculitis

[1]  G. Sebastiani,et al.  [Antineutrophil cytoplasmic antibodies]. , 2011, Reumatismo.

[2]  S. Riviére.  A staged approach to the treatment of Wegener's granulomatosis , 2000 .

[3]  C. Langford,et al.  A staged approach to the treatment of Wegener's granulomatosis: induction of remission with glucocorticoids and daily cyclophosphamide switching to methotrexate for remission maintenance. , 1999, Arthritis and rheumatism.

[4]  K. Sone,et al.  Corticosteroids in the treatment of the acute phase of Kawasaki disease. , 1999, The Journal of pediatrics.

[5]  D. Bullard,et al.  Roles of leukocyte/endothelial cell adhesion molecules in the pathogenesis of vasculitis. , 1999, The American journal of medicine.

[6]  G. Remuzzi,et al.  Mycophenolate Mofetil for the Treatment of Takayasu Arteritis: Report of Three Cases , 1999, Annals of Internal Medicine.

[7]  M. Haubitz,et al.  Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: a prospective, randomized study. , 1998, Arthritis and rheumatism.

[8]  M. Haubitz,et al.  Cyclosporin for the prevention of disease reactivation in relapsing ANCA-associated vasculitis. , 1998, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[9]  B. Han,et al.  Takayasu's arteritis: assessment of disease activity with contrast-enhanced MR imaging. , 2000, AJR. American journal of roentgenology.

[10]  B. Ludviksson,et al.  Active Wegener's granulomatosis is associated with HLA-DR+ CD4+ T cells exhibiting an unbalanced Th1-type T cell cytokine pattern: reversal with IL-10. , 1998, Journal of immunology.

[11]  E. Nordborg,et al.  No additive effect of cyclosporin A compared with glucocorticoid treatment alone in giant cell arteritis: results of an open, controlled, randomized study. , 1998, British journal of rheumatology.

[12]  B. Hoen,et al.  A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. , 1997, Arthritis and rheumatism.

[13]  G. Hughes,et al.  Immunosuppressive treatment in severe connective tissue diseases: effects of low dose intravenous cyclophosphamide , 1997, Annals of the rheumatic diseases.

[14]  C. Gordon,et al.  Damage occurs early in systemic vasculitis and is an index of outcome. , 1997, QJM : monthly journal of the Association of Physicians.

[15]  D. Adu,et al.  Controlled trial of pulse versus continuous prednisolone and cyclophosphamide in the treatment of systemic vasculitis. , 1997, QJM : monthly journal of the Association of Physicians.

[16]  S. Stewart,et al.  Treatment of refractory Wegener's granulomatosis with humanized monoclonal antibodies. , 1996, QJM : monthly journal of the Association of Physicians.

[17]  M. Heller,et al.  Therapy for the maintenance of remission in sixty-five patients with generalized Wegener's granulomatosis. Methotrexate versus trimethoprim/sulfamethoxazole. , 1996, Arthritis and rheumatism.

[18]  P. D. de Jong,et al.  Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. , 1996, The New England journal of medicine.

[19]  G. Hunder,et al.  Long-term survival of patients with Wegener's granulomatosis from the American College of Rheumatology Wegener's Granulomatosis Classification Criteria Cohort. , 1996, The American journal of medicine.

[20]  C. Kallenberg,et al.  Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis , 1996 .

[21]  Guy Hoffman,et al.  Cyclophosphamide-Induced Cystitis and Bladder Cancer in Patients with Wegener Granulomatosis , 1996, Annals of Internal Medicine.

[22]  B. Haynes,et al.  Pathogenic mechanisms of vessel damage in vasculitis syndromes. , 1995, Rheumatic diseases clinics of North America.

[23]  C. Weyand,et al.  Giant cell arteritis as an antigen-driven disease. , 1995, Rheumatic diseases clinics of North America.

[24]  Ansell Bm,et al.  Vasculitis in children and adolescents. , 1995 .

[25]  Bacon Pa,et al.  Vasculitis associated with connective tissue disorders. , 1995 .

[26]  D. Adu,et al.  Endothelial cells and renal epithelial cells do not express the Wegener's autoantigen, proteinase 3 , 1995, Clinical and experimental immunology.

[27]  C. Trépo,et al.  Polyarteritis Nodosa Related to Hepatitis B Virus A Prospective Study with Long‐Term Observation of 41 Patients , 1995, Medicine.

[28]  W. Gross,et al.  Treatment of anti‐neutrophil cytoplasmic antibody (ANCA)‐associated systemic vasculitis with high‐dose intravenous immunoglobulin , 1995, Clinical and experimental immunology.

[29]  Guy Hoffman,et al.  An analysis of forty-two Wegener's granulomatosis patients treated with methotrexate and prednisone. , 1995, Arthritis and rheumatism.

[30]  R. Porter.  Nomenclature of Systemic Vasculitides: Proposal of an International Consensus Conference , 1995 .

[31]  G. Hoffman,et al.  Treatment of corticosteroid-resistant giant cell arteritis. , 1995, Rheumatic diseases clinics of North America.

[32]  M. Daha,et al.  Detachment and cytolysis of human endothelial cells by proteinase 3 , 1994, European journal of immunology.

[33]  P. D. de Jong,et al.  Serum levels of soluble adhesion molecules intercellular adhesion molecule 1, vascular cell adhesion molecule 1, and E-selectin in patients with Wegener's granulomatosis. Relationship to disease activity and relevance during followup. , 1994, Arthritis and rheumatism.

[34]  P. Limburg,et al.  Activation of granulocytes by anti‐neutrophil cytoplasmic antibodies (ANCA): a FcγRII‐dependent process , 1994, Clinical and experimental immunology.

[35]  R. Moots,et al.  Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. , 1994, QJM : monthly journal of the Association of Physicians.

[36]  C. Stegeman,et al.  Activation of granulocytes by anti‐neutrophil cytoplasmic antibodies (ANCA) in Wegener's granulomatosis: a predominant role for the IgG3 subclass of ANCA , 1994, Clinical and experimental immunology.

[37]  S. Jordan,et al.  Treatment of autoimmune diseases and systemic vasculitis with pooled human intravenous immune globulin. , 1994, Clinical and experimental immunology.

[38]  M. Heller,et al.  Influence of disease manifestation and antineutrophil cytoplasmic antibody titer on the response to pulse cyclophosphamide therapy in patients with Wegener's granulomatosis. , 1994, Arthritis and rheumatism.

[39]  D. Underwood,et al.  Epitopes on proteinase-3 recognized by antibodies from patients with Wegener's granulomatosis. , 1994, Journal of immunology.

[40]  C. Kallenberg,et al.  Neutrophil activation in vitro and in vivo in Wegener's granulomatosis. , 1994, Kidney international.

[41]  R J Falk,et al.  Nomenclature of systemic vasculitides. Proposal of an international consensus conference. , 1994, Arthritis and rheumatism.

[42]  R. Moots,et al.  Birmingham Vasculitis Activity Score , 1993 .

[43]  D. Adu,et al.  Relapses in patients with a systemic vasculitis. , 1993, The Quarterly journal of medicine.

[44]  K. Meyer zum Büschenfelde,et al.  Human endothelial cells express proteinase 3, the target antigen of anticytoplasmic antibodies in Wegener's granulomatosis. , 1993, Blood.

[45]  S. Slavin.  Treatment of life-threatening autoimmune diseases with myeloablative doses of immunosuppressive agents: experimental background and rationale for ABMT. , 1993, Bone marrow transplantation.

[46]  J. Liu,et al.  FK506 and cyclosporin, molecular probes for studying intracellular signal transduction. , 1993, Immunology today.

[47]  J. Liu.  FK506 and ciclosporin: molecular probes for studying intracellular signal transduction. , 1993, Trends in pharmacological sciences.

[48]  Guy Hoffman,et al.  The treatment of Wegener's granulomatosis with glucocorticoids and methotrexate. , 1992, Arthritis and rheumatism.

[49]  D. Jayne.  Intravenous immunoglobulin in the therapy of systemic vasculitis , 1992 .

[50]  Guy Hoffman,et al.  Wegener Granulomatosis: An Analysis of 158 Patients , 1992, Annals of Internal Medicine.

[51]  L. A. Healey.  Relation of giant cell arteritis to polymyalgia rheumatica. , 1991, Bailliere's clinical rheumatology.

[52]  C. Pusey,et al.  Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies. , 1991, Kidney international.

[53]  M. Dillon,et al.  Clinical aspects of 100 patients with Kawasaki disease. , 1991, Archives of disease in childhood.

[54]  R. Goldschmeding,et al.  Autoimmunity to lysosomal enzymes: new clues to vasculitis and glomerulonephritis? , 1991, Immunology today.

[55]  M. Yaron,et al.  Methotrexate: mechanism of action in rheumatoid arthritis. , 1990, Seminars in arthritis and rheumatism.

[56]  Guy Hoffman,et al.  Treatment of Wegener's granulomatosis with intermittent high-dose intravenous cyclophosphamide. , 1990, The American journal of medicine.

[57]  S. Ito,et al.  Therapeutic effect of 15‐deoxyspergualin on the progression of lupus nephritis in MRL mice. I. Immunopathological analyses , 1990, Clinical and experimental immunology.

[58]  J. Newburger,et al.  The treatment of Kawasaki syndrome with intravenous gamma globulin. , 1986 .

[59]  C. Savage,et al.  Microscopic polyarteritis: presentation, pathology and prognosis. , 1985, The Quarterly journal of medicine.

[60]  J. Kovarsky.  Clinical pharmacology and toxicology of cyclophosphamide: emphasis on use in rheumatic diseases. , 1983, Seminars in arthritis and rheumatism.

[61]  A. Rees,et al.  PROGNOSIS AFTER IMMUNOSUPPRESSION OF PATIENTS WITH CRESCENTIC NEPHRITIS REQUIRING DIALYSIS , 1983, The Lancet.

[62]  B. Haynes,et al.  Cyclophosphamide therapy of severe systemic necrotizing vasculitis. , 1979, The New England journal of medicine.

[63]  C. Lockwood,et al.  Reversal of impaired splenic function in patients with nephritis or vasculitis (or both) by plasma exchange. , 1979, The New England journal of medicine.

[64]  R. Deremee,et al.  Wegener's granulomatosis. Anatomic correlates, a proposed classification. , 1976, Mayo Clinic proceedings.

[65]  Orchard Tj.  Letter: Mobile coronary care. , 1974 .

[66]  A. Fraga,et al.  Takayasu's arteritis: frequency of systemic manifestations (study of 22 patients) and favorable response to maintenance steroid therapy with adrenocorticosteroids (12 patients). , 1972, Arthritis and rheumatism.

[67]  S. Sheps,et al.  Long-term follow-up study of periarteritis nodosa. , 1966, The American journal of medicine.

[68]  E W WALTON,et al.  Giant-cell Granuloma of the Respiratory Tract (Wegener's Granulomatosis) , 1958, British medical journal.

[69]  J. L. Fahey,et al.  Wegener's granulomatosis. , 1954, The American journal of medicine.

[70]  Sidor Misović,et al.  [Takayasu arteritis]. , 2005, Medicinski pregled.

[71]  J. H. Stone.  Polyarteritis nodosa. , 2002, JAMA.

[72]  W. R. Lee,et al.  Takayasu's arteritis: assessment of disease activity with contrast-enhanced MR imaging. , 2000, AJR. American journal of roentgenology.

[73]  R. Luqmani,et al.  A multi-centre randomised trial of cyclophosphamide versus azathioprine during remission in ANCA-associated systemic vasculitis (Cycazarem). , 1999 .

[74]  K. Raza,et al.  Localized bowel vasculitis: postoperative cyclophosphamide or not? , 1999, Arthritis and rheumatism.

[75]  W. Gross.  New concepts in treatment protocols for severe systemic vasculitis. , 1999, Current opinion in rheumatology.

[76]  R. Moots,et al.  Examination of disease severity in systemic vasculitis from the novel perspective of damage using the vasculitis damage index (VDI). , 1998, British journal of rheumatology.

[77]  P. Callard,et al.  Treatment of glomerulonephritis in microscopic polyangiitis and Churg-Strauss syndrome. Indications of plasma exchanges, Meta-analysis of 2 randomized studies on 140 patients, 32 with glomerulonephritis. , 1997, Annales de medecine interne.

[78]  M. Heller,et al.  Response to trimethoprim/sulfamethoxazole in Wegener's granulomatosis depends on the phase of disease. , 1996, QJM : monthly journal of the Association of Physicians.

[79]  O. Lortholary,et al.  Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. , 1996, Medicine.

[80]  F. Breedveld,et al.  Vasculitis: mechanisms of injury , 1996 .

[81]  M. Feldmann,et al.  Role of cytokines in rheumatoid arthritis. , 1996, Annual review of immunology.

[82]  B. Ansell.  The Vasculitides: Science and practice , 1996 .

[83]  P. Bacon,et al.  Vasculitis associated with connective tissue disorders. , 1995, Rheumatic diseases clinics of North America.

[84]  C. Kallenberg,et al.  Association of Chronic Nasal Carriage of Staphylococcus aureus and Higher Relapse Rates in Wegener Granulomatosis , 1994, Annals of Internal Medicine.

[85]  J. Rice,et al.  Cyclosporin A therapy for Wegener's granulomatosis. , 1993, Advances in experimental medicine and biology.

[86]  E. Reinhold-Keller,et al.  Effectiveness of cyclophosphamide pulse treatment in Wegener's granulomatosis. , 1993, Advances in experimental medicine and biology.

[87]  H. Peter,et al.  Increased expression of CD25 and adhesion molecules on peripheral blood lymphocytes of patients with Wegener's granulomatosis (WG) and ANCA positive vasculitides. , 1993, Advances in experimental medicine and biology.

[88]  C. Pusey,et al.  Anti-neutrophil cytoplasmic antibodies and disease activity during long-term follow-up of 70 patients with systemic vasculitis. , 1991, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[89]  S. McCarthy,et al.  Heterogeneity of the endothelial cell and its role in organ preference of tumour metastasis. , 1991, Trends in pharmacological sciences.

[90]  B. Haynes,et al.  Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. , 1983, Annals of internal medicine.